PLGA(75:25)(poly(lactic-co-glycolic acid))
(Synonyms: 聚乳酸-羟基乙酸共聚物; poly(lactic-co-glycolic acid) 目录号 : GC30049
PLGA. 聚乳酸-羟基乙酸共聚物 (poly (lactic-co-glycolic acid),PLGA)由两种单体——乳酸和羟基乙酸随机聚合而成,是一种可降解的功能高分子有机化合物,具有良好的生物相容性、无毒、良好的成囊和成膜的性能,被广泛应用于制药、医用工程材料和现代化工业领域PLGA@Icaritin NPs与游离Icaritin相比,可以显著抑制细胞生长,诱导乳酸脱氢酶(LDH)渗漏,在G2期阻滞更多的GC细胞,抑制GC细胞的侵袭和转移。
Cas No.:34346-01-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PLGA(poly (lactic-co-glycolic acid)) is made by random polymerization of two monomers: lactic acid and glycolic acid. It is a degradable functional polymer organic compound with good biocompatibility, non-toxic, and good cystforming and film forming properties. It is widely used in pharmaceutical, medical engineering materials and modern industrial fields[1,2].
PLGA@Icaritin nanoparticles (NPs) dramatically suppressed cell growth, induced Lactic dehydrogenase (LDH) leakage, arrested more GC cells at G2 phase, and inhibited the invasion and metastasis of GC cells, compared to free icaritin. In addition, PLGA@Icaritin could help generate dozens of reactive oxygen species (ROS) within GC cells, following by significant mitochondrial membrane potentials (MMPs) loss and excessive production of oxidative-mitochondrial DNA (Ox-mitoDNA)[3].
References:
[1]. Gentile P, Chiono V, et,al. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014 Feb 28;15(3):3640-59. doi: 10.3390/ijms15033640. PMID: 24590126; PMCID: PMC3975359.
[2]. Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, et,al.PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15(2):517-35. doi: 10.7314/apjcp.2014.15.2.517. PMID: 24568455.
[3]. Xiao Y, Yao W, et,al.Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer. Drug Deliv. 2022 Dec;29(1):1712-1725. doi: 10.1080/10717544.2022.2079769. PMID: 35635307; PMCID: PMC9176696.
PLGA. 聚乳酸-羟基乙酸共聚物 (poly (lactic-co-glycolic acid),PLGA)由两种单体——乳酸和羟基乙酸随机聚合而成,是一种可降解的功能高分子有机化合物,具有良好的生物相容性、无毒、良好的成囊和成膜的性能,被广泛应用于制药、医用工程材料和现代化工业领域[1,2]
PLGA@Icaritin NPs与游离Icaritin相比,可以显著抑制细胞生长,诱导乳酸脱氢酶(LDH)渗漏,在G2期阻滞更多的GC细胞,抑制GC细胞的侵袭和转移。此外,PLGA@Icaritin可以帮助在GC细胞内产生数十种活性氧(ROS),造成显著的线粒体膜电位(MMPs)损失和氧化线粒体DNA (Ox-mitoDNA)的过度产生[3]。
|
Protocol 1 (Synthesis of PLGA@ Icaritin )[1]： |
| 1.PLGA-PEG copolymers (PEG2000) were prepared by melt polymerization under vacuum using stannous octoate [stannous 2-ethylhexanoate] as a catalyst. PLGA and PEG2000 (0.77 g) (45%/w) were heated to 140℃ in a bottleneck flask under a nitrogen atmosphere for complete melting. (The molar ratio of DL-lactide to glycolide was 3:1 in PLGA) 2.Stannous octoate [0.05% (w/w)] was added, and the temperature of the reaction mixture was increased to 180℃. This temperature was maintained for 4 h. Polymerization was performed under vacuum. 3.The copolymer was recovered by dissolution in methylene chloride, followed by precipitation in ice-cold diethyl ether. After 24 h, PLGA-PEG was purified by washing with ethanol and drying under vacuum. 4.Icaritin (0.5 mg) was dissolved in 500 μL dimethyl sulfoxide and mixed with 5 mg of PLGA-PEG in the drug solution. 5.The drug-polymer mixture was added dropwise to 10 mL of deionized water while stirring and stirred for 24 h at room temperature in a beaker. 6.PLGA@Icaritin was obtained, dialyzed to remove the organic solvent, and freeze-dried.
|
|
References: [1]. Xiao Y, Yao W, et,al. Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer. Drug Deliv. 2022 Dec;29(1):1712-1725. doi: 10.1080/10717544.2022.2079769. PMID: 35635307; PMCID: PMC9176696. |
| Cas No. | 34346-01-5 | SDF | |
| 别名 | 聚乳酸-羟基乙酸共聚物; poly(lactic-co-glycolic acid | ||
| Canonical SMILES | O=C(O)C(C)OC(CO[H])=O.[x].[y] | ||
| 分子式 | (C5H8O5)n | 分子量 | 10000-20000 |
| 溶解度 | DMSO : 100 mg/mL ;chloroform : 16.67 mg/mL ;Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.1 mL | 0.5 mL | 1 mL |
| 5 mM | 0.02 mL | 0.1 mL | 0.2 mL |
| 10 mM | 0.01 mL | 0.05 mL | 0.1 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch: